CCT2 and prostate carcinoma: In addition, the expression levels of three proteins—TUFM, and HNRNPH3 from the DHT-specific proteome, and CCT2 from the FSK-specific proteome—were related to the progression-free interval in prostate cancer patients (Figure 6b).